Access Pharma Aiming to Aid in Ovarian Cancer Fight
There has been new research announced in an article on Bloomberg's Business Week that discusses mutated genes and the impact on the likelihood of getting ovarian cancer. In this arena, neurotoxicity in therapies has also been a constant bane in the side of researchers, drug manufacturers (and, subsequently, patients).
Zack's Notes Uptrend in Keryx Biopharmaceuticals ($KERX)
Zacks.com, a leader in investment research, has aptly noted the recent uptrend in the share price of Keryx Biopharmaceuticals (NASDAQ: KERX, Stock Twits: $KERX) over the last several weeks. Zack’s “SmarTrend” analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time.
Medical Billing Assistance (MDBL) Aims to Provide MRIs for Rural America
The Cost of Diagnostics Versus the Cost of a Young Athlete’s Life
A press release from Vicor Technologies, Inc. was released yesterday that basically commented on the state of the industry as it relates to the costs versus the benefits of more thorough testing of athletes to determine the risk of a sudden cardiac incident. It is indeed and eye-opener as to how money rules our world today. The original news link to the PR is provided (linked to Yahoo Finance).
Cellceutix Drug Outperforming Current Chemotherapies in Fight Against Leukemia
Cellceutix has been releasing a host of information about the activity of Kevetrin, its lead compound for the treatment of drug-resistant cancers. Early research has shown Kevetrin to demonstrate significant tumor reduction and growth suppression in strains of breast, lung and colon cancers.
Stocks Advance Prior to Phase III FDA Approval...Is Ventrus (VTUS) Next?
Cellceutix Announces Kevetrin Non-Genotoxic as Cancer Therapy
Cellceutix Corporation has made two significant announcements this week pertaining to Kevetrin, their flagship compound for the treatment of drug-resistant cancers. Not only has pre-clinical data produced very promising data as a therapy for breast, lung and colon cancer, the recent data as clinical trials approach this year can only be considered big news for the cancer industry.